TBCRC048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded) - Tung, N M; Robson, M E; Ventz, S (J Clin Oncol, 2020)